Efpeglenatide, developed by Sanofi, is positioned as a once-weekly GLP-1 receptor agonist for the treatment of Type 2 Diabetes Mellitus (T2DM). The asset aims to demonstrate non-inferiority to Dulaglutide, a well-established competitor in the GLP-1 market. The termination of the trial was due to a sponsor decision rather than safety concerns, which may indicate strategic repositioning or resource allocation towards other assets. The competitive landscape includes other GLP-1 therapies, and successful outcomes could enhance market share in a growing diabetes treatment market, which is projected to expand significantly due to increasing prevalence of diabetes globally.